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This multicentre phase II study was designed to evaluate the antitumour activity and toxicity of bifractionated camptothecin (CPT-11)
and 5-fluorouracil/ leucovorin (5-FU/LV) in the treatment of patients with metastatic colorectal cancer (MCC) who had been
pretreated with 5-FU/LV-oxaliplatin (FOLFOX regimen). In all, 35 patients were enrolled in a two-stage trial. Treatment consisted of
two daily doses of CPT-11, 90mgm
2 administered over 90min, followed by LV, 200mgm
2 administered over 2h plus 5-FU
400mgm
2 as a bolus and 600mgm
2 as a 22-h continuous infusion administered with disposable pumps as outpatient therapy.
Toxicity was closely monitored. Response was evaluated by computed tomography scans every 8 weeks. All 35 patients were
assessable for toxicity and response to treatment. Seven patients had a partial response, giving an overall response rate of 20%; 11
patients had stable disease (31.4%) and 17 progressed (48.5%). The median progression-free survival was 7.1 months and median
survival was 14 months. A total of 10 patients (30%) experienced grade 3–4 toxicity, including nausea (15%), diarrhoea (12%) and
neutropenia (15%), while seven patients (21%) had grade 2 alopecia. The bifractionated bimonthly schedule of CPT-11 plus 5-FU/LV
showed substantial antitumour activity and was well tolerated in this group of patients with a poor prognosis, pretreated with the
FOLFOX regimen.
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Colorectal carcinoma, the second most common cancer in Europe,
accounts for 80000 to 95000 deaths each year (Black et al, 1997).
Systemic chemotherapy has gained a key role in the treatment of
colorectal cancer: in the adjuvant setting it decreases the chance of
recurrence and improves survival in patients with node-positive
tumours (O’Connell et al, 1997), whereas in the setting of
metastatic disease it delays the onset of tumour-related symptoms
and extends survival (Nordic Gastrointestinal Tumour Adjuvant
Therapy Group, 1992). Two recently introduced drugs active in the
treatment of MCC are the camptothecin analog irinotecan (CPT-
11) and oxaliplatin (L-OHP). Owing to the fact that these drugs
have completely different mechanisms of action, they do not
present crossresistance: CPT-11 inhibits cell division by inactiva-
tion of topoisomerase I (Jaxel et al, 1989) and is non-crossresistant
with 5-fluorouracil (5-FU), while L-OHP forms DNA adducts
leading to the inhibition of DNA synthesis (Raymond et al, 1998).
Both drugs have been shown, in vitro, to have synergistic effects
with 5-FU and leucovorin (LV) on colorectal cancer cell lines
(Mullany et al, 1998; Raymond et al, 1998). In Europe, L-OHP
combined with LV and infusional 5-FU was approved in 1999 as
the first-line treatment of metastatic colorectal cancer (MCC) (de
Gramont et al, 2000), whereas in North America, a combination of
CPT-11 with 5-FU and LV administered as an intravenous (i.v.)
bolus (Saltz et al, 2000) has been adopted. The FOLFOX regimen
(L-OHP and infusional 5-FU plus LV) has recently been reported
to be active and comparatively safe and is now recommended as
the standard therapy for patients with advanced colorectal cancer
(Goldberg et al, 2004). In second-line therapy, the association of L-
OHP with 5-FU/LV in the treatment of patients with MCC
progressing after CPT-11/5-FU/LV (FOLFIRI regimen) has been
shown to be beneficial (Rothenberg et al, 2003) and limited data
from literature exist on the salvage treatment of patients with MCC
progressing after the FOLFOX regimen. In patients with resistance
to 5-FU bolus, CPT-11 has been shown to be superior both with
respect to best supportive care and to 5-FU continuous infusion
(Cunningham et al, 1998; Rougier et al, 1998). A modest survival
gain was obtained with this treatment, but was accompanied
by severe gastrointestinal toxicity, with an elevated percentage
of patients having to be hospitalised during the course of
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lchemotherapy. Such high toxicity has decreased the potentially
universal adoption of CPT-11 in the treatment of MCC (O’Connell,
1998).
It has been shown that CPT-11 efficacy and toxicity are both
schedule and dose dependent (Albigerges et al, 1995; Guichard
et al, 1997). In a previous study in a group of 54 patients with
MCC, the dose of CPT-11, administered as first-line chemotherapy,
was split over 2 days and administered with the ‘de Gramont’
regimen in order to decrease the toxicity profile and to better
exploit the synergistic action of CPT-11, 5-FU and LV (Recchia
et al, 2003). As a modest toxicity profile with an activity
comparable to other CPT-11-based regimens was observed, in
the present study, we have treated a cohort of patients with MCC
progressing after the FOLFOX regimen, with bifractionated CPT-11
and bimonthly L-OHP and 5-FU.
PATIENTS AND METHODS
Eligibility criteria
Patients previously treated with the FOLFOX regimen for
metastatic disease were enrolled in the study. Disease progression
had to have occurred during or within 6 months after L-OHP/5-
FU/LV-based chemotherapy for metastatic disease. Patients had to
be at least 18 years old and ambulatory, with an Eastern
Cooperative Oncology Group (ECOG) performance status (PS)
p2. The study included only patients with a life expectancy
of at least 12 weeks and adequate haematological reserve
and hepatic and renal function, documented by WBC
X3000mm
3, absolute neutrophil count X1500mm
3, haemoglobin
level 49.0gdl, platelets X100000mm
3, serum bilirubin
X1.5mgdl, aspartate aminotransferase and alanine aminotrans-
ferase o4 times the upper limit of normal) and normal cardiac
and renal functions (ejection fraction 450%, serum creatinine
p2.0mgdl).
Patients with additional malignancies, other than curatively
treated skin and cervical cancer or with active cardiovascular
disease, were excluded. Patients treated with palliative radiation
therapy were entered if previous treatment did not involve the
lesion used for the measurement of response. The protocol was
approved by the Ethical Committee of the Civilian Hospital of
Avezzano, Italy and of the other participating institutions, and
written informed consent was obtained from each patient.
Chemotherapy
Following an initial assessment, a single lumen Hickman line or a
port-a-cath was positioned into the subclavian vein under local
anaesthesia. Patients were instructed in catheter care and heparin
flush technique. Chemotherapy was administered on an outpatient
basis for 2 consecutive days and was repeated every 2 weeks until
disease progression, unacceptable toxicity or refusal. According to
in vitro studies that had shown that the schedule of administration
was a critical parameter for chemotherapeutic efficacy (Guichard
et al, 1997), CPT-11 was given as the first drug at the dose
of 90mgm
 2 in 250ml of 5% dextrose in water over 90min.
Atropine and loperamide were used according to the manufac-
turer’s guidelines. LV 200mgm
 2 was administered as a 2-h i.v.
infusion, followed by 5-FU 400mgm
 2 as a bolus; 5-FU
600mgm
 2 was administered as a 22-h continuous infusion over
2 consecutive days with elastomeric pumps. Routine antihemetic
prophylaxis with a 5-hydroxytryptamine-3 receptor antagonist was
carried out.
Patients were assessed for toxicity before each cycle of
chemotherapy using WHO criteria (Miller et al, 1981). CPT-11
dosage was modified according to the level of toxicity occurring
during the previous course of chemotherapy.
Pretreatment and follow-up evaluation
Before treatment, a complete history was taken and a physical
examination was performed. Weight was recorded and a complete
blood count, differential, serum bilirubin, creatinine, albumin,
alkaline phosphatase, transaminases, lactic dehydrogenase and
carcinoembryonic antigen (CEA) were determined. Initial radi-
ological investigations included chest X-ray and computed
tomography of the abdomen and pelvis. Blood counts were
repeated weekly, serum biochemistry was determined before each
course of treatment and CEA and radiological investigations were
repeated every 8 weeks (four courses of chemotherapy) or sooner,
if clinically indicated. An X-ray skeletal survey was performed
when abnormal areas of uptake were observed in bone scans; CT
scanning was used to evaluate hepatic lesions. Before each
subsequent course of treatment, all patients had a further complete
blood cell count, plasma urea, electrolytes, serum creatinine and
liver function tests. In addition, a full blood count was repeated
weekly. Follow-up visits were performed bimonthly. Objective
responses and toxicity were evaluated according to WHO criteria
(Miller et al, 1981).
Dose intensity (DI), calculated according to the Hryniuk method
(Hryniuk, 1988), was considered as the number of milligrams of
the drug per square meter per week during treatment from day 1 of
the first cycle to day 15 of the last course of chemotherapy.
Planned DI was 90mgm
2 per week for CPT-11, 200mgm
2 for LV
and 1000mgm
2 for 5-FU.
Statistical considerations
The study was designed as a two-stage trial with an interim
analysis after treatment of the first group of 18 patients (Simon,
1989). A response rate of 410% was required for the trial to
continue. Taking into consideration a 90% response detection rate,
in a cohort of 18 evaluable patients, the trial would have
terminated if there were p2 responses. As there were 43 partial
responses, the trial continued with the enrolment of an additional
17 patients for a total of 35 patients. The primary end points of the
study were response rate and toxicity; secondary end points were
time to progression and survival. For the response rate, exact
binomial 95% confidence intervals (CI) were calculated. Time to
progression was measured from the date of the first course of
treatment to the date of relapse or last follow-up. Survival was
determined from the date of the first course of treatment to the
date of death, or 31 December 2003 for surviving patients. Both
were assessed by means of the Kaplan and Meier product-limit
method (Kaplan and Meier, 1958). The overall survival and toxicity
results are presented on an intent-to-treat basis.
RESULTS
Patients’ characteristics
From January 2000 to December 2002, 35 patients with MCC were
enrolled into the trial. Patient’s characteristics and history of
disease are summarised in Table 1. The median age was 55 years
(range 31–79 years ) and 74% of patients were males. In all, 74% of
patients had colon carcinoma, while 26% had rectal carcinoma. All
the patients were pretreated with the FOLFOX regimen for
metastatic disease and had received a median number of eight
courses of such therapy. A total of 25 patients (71%) had liver
metastases, 29% had lung disease and 40% had nodal involvement.
In total, 83% percent of patients had a good performance status.
Responses to the previous FOLFOX regimen were as follows: three
complete responses (5.6%), 24 partial responses (44.4%), for an
overall response rate of 50% (95% CI: 36–64%). The median time
to progression and overall survival were 10.3 and 19.2 months,
respectively (Recchia et al, 2004).
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A total of 251 courses of chemotherapy were administered, with a
median number of six courses per patient (range 2–26). All 35
patients were evaluated for toxicity and response. According to the
intent-to-treat principle, the following objective remissions were
observed: six patients had partial response, giving an overall
response rate of 17.1% (95% CI: 6.5–33.6%); 13 patients had stable
disease (37.1%) and 16 had disease progression (45.7%). After a
median follow-up of 20 months (minimum 12 months), median
progression-free survival was 7.3 months (range 2.8–43.2 months)
(Figure 1), while median survival was 14 months (range 1.2–45.6)
(Figure 2). The estimated 1-year survival rate was 55%; however,
median survival, calculated from the start of FOLFOX treatment as
first-line chemotherapy, was 27 months (range 8.2–59.7 months).
Palliative radiotherapy was administered to six patients. The
number of instances of disease progression occurring in the
following sites was: liver 22, locoregional 8, lung 7, bones 5, brain,
peritoneum and nodes, 2 instances each. A total of 25% of patients
were salvaged with gemcitabine modulated by 5-FU/LV and with a
continuous infusion of 5-FU/carboplatin.
The median DI delivered was 96% for all drugs. The DI of CPT-
11 was 84mgm
 2w
 1, while the DIs of LV and 5-FU were 192 and
960mgm
 2w
 1, respectively, similar to planned DIs.
Toxicity
Toxicity data for the 35 patients are summarised in Table 2. No
treatment-related death was observed. Grade 3–4 diarrhoea
occurred in six patients (18%). Such a low complication rate
may be explained by the low daily dose of CPT-11. In fact, a phase I
study demonstrated that the gastrointestinal toxicity induced by
CPT-11 increased in intensity with greater doses of the drug
(Albigerges et al, 1995). Leukopenia grade 3–4 occurred in six
patients (18%). Grade 3–4 thrombocytopenia was low and was
observed in three patients (9%) only. Hepatic toxicity (abnormality
of liver enzymes) was observed in six patients (18%); however, two
of these patients indulged in alcohol consumption. In all, 40% of
patients had no nausea or vomiting. Mild skin toxicity occurred in
six patients (17%). Severe alopecia was observed in 11% of
patients. Catheter-related complications (displacement, infection)
were observed in four patients, all of whom had the catheter
removed and a second catheter inserted. Treatment was delayed in
42 courses of chemotherapy (7%).
DISCUSSION
This multicentre phase II study was designed to assess the activity
and toxicity of CPT-11 administered over 2 days, combined with a
Table 1 Characteristics of patients
Characteristics No. %
No of patients 35 100
Age (years)
Median 55
Range 31–79
Sex
Males 26 74
Females 9 26
Performance status (ECOG)
0–1 29 83
26 1 7
Site of primary disease
Colon 26 74
Rectum 9 26
Stage at diagnosis
IIB 3 8
IIIB 2 6
IIIC 7 20
IV 23 66
Prior therapy
Surgery 30 86
Radiotherapy 9 26
Adjuvant chemotherapy 10 28
No of previous chemotherapy
First line 16 46
Second line 16 46
XThird line 3 8
Metastatic sites
Liver 25 71
Lung 10 29
Nodes 14 40
Bones 3 9
Pelvic local recurrence 6 17
Peritoneum 8 23
Rising serum markers 1 3
No of metastatic sites
11 8 5 1
21 3 3 7
X34 1 1
ECOG¼Eastern Cooperative Oncology Group.
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Figure 2 Overall survival. Events 27 (77.1%), censored 8 (22.8%) and
median overall survival 14 months (range 1.2–45.6 months).
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Figure 1 Time to progression. Events 37 (94.2%), censored 2 (5.8%)
and median time to progression 7.3 months (range 2.8–43.2 months).
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with MCC who had been pretreated with the FOLFOX regimen as
first-line chemotherapy. The objective response rate was 17.1%
(95% CI: 6.5–33.6%) and median progression-free survival was 7.3
months. An overall clinical benefit was observed in 54% of
patients. The relatively long median survival of 14 months from
the start of the second-line chemotherapy and 27 months from the
diagnosis of metastatic disease, that is, from the administration of
the FOLFOX regimen as first-line treatment, may be explained by
the fact that two patients with a partial response underwent liver
resection of residual metastatic disease and are still alive after 43
and 45 months, respectively, and 25% of patients received a third
line of chemotherapy with 5-FU modulated by gemcitabine. The
administration of a third line of chemotherapy to our patients has
been made possible due to the low-toxicity profile resulting from
the bifractionated administration of both L-OHP in first-line
chemotherapy and campthotecin in second-line chemotherapy.
The lower daily dose of CPT-11 decreases the peak plasma level,
thus decreasing the toxicity profile, while efficacy is not altered
(Albigerges et al, 1995). In view of the palliative intents that
chemotherapy accomplishes in the treatment of pretreated color-
ectal cancer, current approaches should be designed to find active
but less toxic drug combinations. Palliation of symptoms is
important in relatively chemoresistant tumours such as gastro-
intestinal cancers or non-small-cell lung cancer, in which
chemotherapy has no curative intent (O’Connell, 1998). Treatment
compliance for this regimen was good, with median relative DIs
delivered for L-OHP, LV and 5-FU of 92%, 92% and 94%,
respectively.
In the preoxaliplatin era, CPT-11 was shown to be an
active agent in patients with rapidly progressing colorectal
cancer (Rothenberg et al, 1996), in patients refractory to 5-FU
(Rougier et al, 1998) and in patients who had progressed
during or shortly after 5-FU-based chemotherapy (Pitot
et al, 1997). In Rothenberg’s study, however, 23% of
patients developed grade 4 diarrhoea and the other studies
reported a high-toxicity profile with several hospital deaths
attributable to multiple gastrointestinal toxicities, together with
unexpected thromboembolic events (Rothenberg et al, 2001).
The toxicity reported in the American studies was partially
due to the different delivery schedule of CPT-11/LV/5-FU, and in
a study in which CPT-11 was administered on a weekly
basis, diarrhoea was reported in 88.9% of patients (Douillard
et al, 2000). A recently published randomised phase III study has
investigated the efficacy of the alternate sequence of administra-
tion of the FOLFIRI and FOLFOX regimens in the treatment of
MCC (Tournigand et al, 2004). Second-line treatment with
FOLFIRI achieved a 4% response rate with a 2.5 month median
progression-free survival rate and overall survival of 20.6 months
from the start of FOLFOX administered as first-line chemotherapy.
Grade 3–4 neutropenia were observed in 21% of patients. In our
present study, we report a 20% response rate, a median
progression-free survival of 7.1 months and an overall survival
of 27 months with grade 3–4 neutropenia observed in 38% of
patients. This improvement with respect to relatively poor efficacy
of FOLFIRI as second-line therapy reported in Tournigard’s study
may be due to the fractionated administration of CPT-11, however
at the expenses of a slightly worse toxicity profile. The above
results show that the efficacy of a chemotherapeutic regimen may
be not only dose dependent but also schedule dependent. The
administration of CPT-11 over 2 days has been shown to be
feasible, active and tolerable and our 1-year survival rate of 56%
compares favourably with the 39 and 38% 1-year survival rates
obtained in other trials (Rothenberg et al, 1999, Gil-Delgado et al,
2001) with CPT-11 treatment as second line chemotherapy. As the
question of whether fractionated CPT-11 is more effective than
CPT-11 given as a single dose on day 1 cannot be assessed from a
phase II study, a randomised study comparing fractionated vs 1-
day administration of CPT-11 with 5FU/LV is shortly planned to
clarify this issue.
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Table 2 Toxicity according to WHO criteria
WHO grade
0 1 2 3 4 Total
No. % No. % No. % No. % No. % No. %
Haematologic
Leucopenia 12 34 6 17 11 31 4 12 2 6 35 100
Neutropenia 11 31 4 11 7 20 9 27 4 11 35 100
Thrombocytopenia 29 82 2 6 1 3 3 9 0 0 35 100
Anaemia 15 43 13 37 4 11 2 6 1 3 35 100
Infection 26 73 6 18 3 9 0 0 0 0 35 100
Gastrointestinal
Oral 22 62 7 20 3 9 2 6 1 3 35 100
Nausea and vomiting 14 40 11 31 7 20 3 9 0 0 35 100
Diarrhoea 14 40 7 20 8 22 6 18 0 0 35 100
Ileus 0 0 0 0 0 0 0 0 0 0 35 100
Hepatic 29 82 6 18 0 0 0 0 0 0 35 100
Neurotoxicity 33 94 2 6 0 0 0 0 0 0 35 100
Triglycerides 0 0 0 0 0 0 0 0 0 0 0 0
Renal 35 100 0 0 0 0 0 0 0 0 35 100
Cutaneous
Alopecia 0 0 15 44 16 45 4 11 0 0 35 100
Skin 29 83 4 11 2 6 0 0 0 0 35 100
WHO¼World Health Organisation.
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